Colgate-Palmolive (NYSE: CL) stock price gained just 6% from $75 in 2017 end to around $80 currently, primarily due to favorable changes in its revenues. During this period, the company witnessed a strong 15% rise in revenues, and combined with a drop in its outstanding share count, its revenue per share actually rose 20%. However, due to a pullback in its P/S multiple over this period, the company managed to gain only 6%. Additionally, over the same period, the S&P 500 returned around 50%, meaning that CL stock underperformed the broader markets since 2017-end.
In our interactive dashboard, Why Colgate-Palmolive Stock Moved: CL Stock Has Gained 6% Since 2017, we break down the factors behind this move.
(A) Colgate-Palmolive’s Total Revenue has grown 15% from $15.5 billion in FY 2017 to $17.7 billion on an LTM basis
- CL’s total revenue rose steadily from $15.5 billion in FY ’17 to $17.4 billion in FY ’21, and demand has picked up strongly since the pandemic, with sales rising to $17.7 billion currently.
- Colgate-Palmolive is a leading producer and distributor of household, health care, personal care, and veterinary products, operating in markets across the world.
- As of FY ’21, Oral, Personal and Home Care sales make up the bulk of CL’s total sales at 81%, with Pet Nutrition making up the remaining 19%.
- For additional details about CL’s revenues and comparison to peers, see Colgate-Palmolive (CL) Revenue Comparison
(B) Revenue per share (RPS) increased 20% from $17.56 in FY 2017 to $21.13 currently
- Colgate-Palmolive revenue rose from $15.5 billion in FY ’17 to $17.7 billion currently, while the outstanding share count decreased from around 880 million in FY 2017 to just a little under 840 million currently.
- Due to this, RPS has jumped from $17.56 in FY ’17 to $21.13 currently.
(C) Price-To-Sales (P/S) multiple for Colgate-Palmolive dropped strongly from 4x in 2017 end to 3.1x by 2018 end but has since pulled back to 3.8x currently, still around 5% lower than what it was in late 2017
- Colgate-Palmolive’s performance since 2017-end first saw its P/S multiple drop from 4x in 2017 to 3.1x in 2018, before rising to as high as 4.2x by 2020 end.
- Despite CL’s strong and consistent sales performance since 2018 and increased demand, the P/S multiple has dropped to 3.8x currently due to increased uncertainty surrounding global economic conditions.
- For additional details about the company’s historical returns and comparison to peers, see Colgate-Palmolive (CL) Stock Return.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
| Returns | Aug 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| CL Return | 1% | -6% | 22% |
| S&P 500 Return | 0% | -14% | 84% |
| Trefis Multi-Strategy Portfolio | 3% | -11% | 251% |
[1] Month-to-date and year-to-date as of 8/5/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
